Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Takeda pharmaceutical company limited save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
CNTG | $0.461 -3.96% -4.12% 23K
|
Commercial Services
|
| O: 1.43%
H: 1.41%
C: -1.41%
partnership genetic takeda disorders
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.46%
C: 0.42%
fda first treatment
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NBIX M | $132.49 -0.56% -0.56% 550K
|
Health Technology
|
| O: -5.57%
H: 6.04%
C: 0.96%
financial results
Announcing Cognizant Flowsource™, a generative AI-enabled platform for powering modern engineering
Published: 2024-02-01 (Crawled : 05:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
CTSH | $67.14 -0.59% -0.6% 4.6M
|
Technology Services
|
| O: 0.3%
H: 0.78%
C: 0.69%
cognizant platform
Takeda Named Global Top Employer for Seventh Consecutive Year
Published: 2024-01-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.13%
H: 0.27%
C: 0.2%
year global
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.36%
H: 0.14%
C: -1.01%
rare services glassia contract treatment blood
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth - Technavio
Published: 2023-11-27 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -4.49%
H: 6.23%
C: 3.42%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.21%
H: 0.21%
C: -1.93%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.28%
C: 0.21%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
VNDA | $4.97 -5.15% -5.43% 3.9M
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -3.01%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
america therapeutics growth market
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Published: 2023-11-17 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.75%
H: 0.32%
C: -0.07%
takhzyro label update group
COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape
Published: 2023-11-06 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.11%
H: 0.33%
C: -0.98%
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: -0.33%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.44%
H: 0.22%
C: 0.07%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.24%
H: 0.18%
C: 0.16%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.55%
H: 0.3%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
covid-19
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
Published: 2023-09-29 (Crawled : 09:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.51%
H: 0.42%
C: -0.26%
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: 0.59%
H: 0.82%
C: -0.65%
drug japan application submission
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.57%
H: 0.38%
C: 0.25%
japan approval
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Published: 2023-09-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.12%
H: 0.43%
C: -0.18%
tak-721 fda resubmission treatment
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.